- Report: Ranbaxy may sell generic Lipitor rights if unable to get FDA approval
- Report: Ranbaxy to market generic Aricept
- Report: Mylan looks to block Ranbaxy from making generic Lipitor
- Report: State Medicaid programs can reap savings with increase in generic drug use
- Ranbaxy generic Lipitor launch delayed as Watson launches authorized generic
PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said Tuesday.
The India-based generic drug maker announced the launch of cevimeline hydrochloride in the 30-mg strength under an agreement with parent company Daiichi Sankyo. The drug is used in patients with Sjogren's syndrome, which affects the moisture-producing glands.
Daiichi Sankyo markets the drug under the name Evoxac. The drug had sales of $62.4 million during the 12-month period ended in June 2011, according to IMS Health.
An authorized generic is a branded drug marketed under its generic name at a lowered price. Apotex is marketing the generic version of the drug.